TMCnet News
SteroidStocks.com Says: (OTCBB:GLOW) - (OTCBB:ORHI) - (OTCBB:ISCO) Are On Steroids!!!(M2 PressWIRE Via Acquire Media NewsEdge) SteroidStocks.com Says: (OTCBB:GLOW) Glowpoint, Inc. , (OTCBB:ORHI) OmniReliant Holdings, Inc. and (OTCBB:ISCO) International Stem Cell Corp. are on STEROIDS! SteroidStocks.com invites all investors to sign up at www.steroidstocks.com to subscribe to our FREE newsletter. To feature your publicly traded company in our alerts email us at [email protected] ----------------------------------------------------------------------------------------------------- About Glowpoint Glowpoint, Inc. (OTCBB: GLOW) enables video users to effortlessly and securely call one another regardless of their video technology or network. With unlimited, "open" access to Glowpoint's cloud-based, hosted-video infrastructure and services, video calling within - and between - companies is dramatically simplified. From full-featured telepresence and video conferencing suites to desktop video, Glowpoint supports customers around the world with 24/7 managed services that allow business professionals to enjoy "in-the-same-room" intimacy and cost savings. To see a video-in-the-cloud demonstration, and to learn more about how cost-effective and easy telepresence and video conferencing can be for your business, email us at [email protected] or visit http://www.glowpoint.com. MEDIA CONTACT: INVESTOR RELATIONS CONTACT: Cheryl Cink, for Glowpoint Jonathan Brust +1 530-756-4630 Glowpoint, Inc. [email protected] +1 312-235-3888, ext. 2052 www.glowpoint.com [email protected] www.glowpoint.com (Logo: http://photos.prnewswire.com/prnh/20100420/GLOWPOINTLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100420/GLOWPOINTLOGO) News Today: HILLSIDE, N.J., Aug 19, 2010 -- Glowpoint, Inc. (OTC Bulletin Board: GLOW), a global provider of managed services for telepresence and video conferencing, today announced that one of the foremost renewable energy development companies, whose policies require its name be kept confidential, has chosen Glowpoint's cloud-based managed video services to reduce executive travel and increase employee collaboration. The energy development company originally implemented Glowpoint's B2B Exchange services (TEN) in early 2009 at four of its corporate sites and has recently expanded its service to include Glowpoint's cloud-based, reservationless and managed multi-point conferencing for inter-office communications. In 2010, the client has utilized their video systems for more than 31,000 minutes, with increasing usage attributed to multi-point video calling enabled by Glowpoint's hosted video infrastructure. Glowpoint Vice President of Marketing Jonathan Brust said, "I am particularly pleased to see companies that are focused on energy conservation adopt video services. With businesses using our cloud-based services, they realize an even greater environmental benefit by providing a shared technology, rather than a redundant, on-premise approach." Glowpoint supports a host of companies in the environmental sector, such as the Sierra Club and Environmental Defense, in addition to providing managed video services to 16 energy-related companies around the world. Glowpoint's cloud-based video services include a secure, redundant, and easily accessible mix of hardware, software, and support services, such as: A web-based, video management portal Exchange and notes integrated scheduling and call launching Continuous remote monitoring, diagnostics, and help desk services Telepresence and video conferencing interoperability Complete business-to-business exchange access Multiple MCU bridges, gateways, gatekeepers, and call routing technology Reservationless - and managed - bridging services Supporting Resources Glowpoint Managed Services Recent Glowpoint News and Events Glowpoint on Twitter ------------------------------------------------------------------------------------------------------ About OmniReliant Holdings OmniReliant Holdings is a holding Company that has company subsidiaries that utilizes DRTV, live shopping and internet to build brands. The Company, through its subsidiaries, engages in the creation, design, distribution, and sale of affordable products available to U.S. and international consumers. The Company successfully markets its products through various direct response formats, live shopping networks, ecommerce, direct mail, and traditional retail channels. The corporate offices of OmniReliant are located 14375 Meyerlake Circle Clearwater, Florida 33760. OmniReliant questions may be addressed to Robert J. DeCecco, CEO, at 727-230-1031. For further information visit http://www.omnireliant.com. Recent News : CLEARWATER, FL, Aug 18, 2010 OmniReliant Holdings, Inc. (OTCBB: ORHI) announces that OmniResponse, the wholly owned consumer products enterprise of OmniReliant Holdings, Inc., is featuring its ColdFire product this Thursday on the season premier of "PitchMen," a popular reality TV series on the Discovery Channel. Beginning its second season, Anthony "Sully" Sullivan continues the search for innovative creations by hopeful inventors that deserve to be pitched. ColdFire will be featured in the "Passing the Torch" segment which airs August 19, 2010 at 9:00 P.M. EDT. In this year's season premiere episode, Sully will be set fully ablaze while doused in ColdFire to prove how reliable the product is at putting out flames quickly and safely. Click here to preview how ColdFire astonishes Sully and crew in a remarkable demonstration. ColdFire is an environmentally friendly solution that instantly extinguishes flames from fuel, wood, fabric, and grease fires while leaving surfaces cool to the touch without any toxic residue! Robert J. DeCecco, CEO of OmniReliant Holdings, parent company of OmniResponse, said, "We are thrilled to be a part of the second season of Discovery Channels' 'PitchMen' series. We anticipate this exposure on 'PitchMen' to achieve a similar success story as our DualSaw Brand which was portrayed in last years inaugural 'PitchMen' series. Our exposure on season one of 'PitchMen' helped generate close to $20 million dollars in sales for the DualSaw in 2009 alone. We believe opportunities like this will further validate and strengthen the ColdFire brand as we look to market this product on a worldwide basis. Management believes this year's episode, which focuses on a life saving product, may lead to further distribution creating greater profits and shareholder value." ----------------------------------------------------------------------------------------------------- ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB) International Stem Cell Corporation is a California-based biotechnology company focused on therapeutic and research products. ISCO's core technology, parthenogenesis, results in creation of pluripotent human stem cells from unfertilized oocytes (eggs). These proprietary cells avoid ethical issues associated with use or destruction of viable human embryos and, unlike all other major stem cell types, can be immune matched and be a source of therapeutic cells with minimal rejection after transplantation into hundreds of millions of individuals across racial groups. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology, develops a line of cosmeceutical products via its subsidiary Lifeline Skin Care and advances novel human stem cell-based therapies where cells have been proven to be efficacious but traditional small molecule and protein therapeutics do not. More information is available at ISCO's website, www.internationalstemcell.com. To subscribe to receive ongoing corporate communications please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0. News Today: OCEANSIDE, Calif., Aug 19, 2010 -- International Stem Cell Corporation (OTCBB:ISCO), www.internationalstemcell.com, today announced that its stem cell therapeutic programs focused on protective, transparent corneas (CytoCor(TM)) in the front of the eye and the light-sensitive retinal tissue (CytoRet(TM)) in the back of the eye will be formalized into a new business unit, Cytovis(TM). Together these programs will leverage external and internal development, regulatory and commercial expertise in cellular ophthalmology to form a focused portfolio of complementary product candidates designed to address high unmet medical needs with apparent pharmacoeconomic and quality of life benefits. CytoCor is the brand name for ISCO's corneal tissue that can be derived from the company's proprietary parthenogenetic stem cells or commonly used embryonic stem cells. Research and development with partners Absorption Systems in the US, Sankara Nethralaya in India and Automation Partnership in the UK continues for the purpose of optimizing the tissue for transplantation in the 10 million people worldwide suffering from corneal vision impairment and as an alternative to the use of live animals and animal eyes in the $500+M market for safety testing of drugs, chemicals and consumer products. ISCO's goal in the coming months is to establish funding and infrastructure in India for accelerated development of CytoCor for the therapeutic application and to advance and implement the chemical testing application with partners in the US and Europe. CytoRet is the brand name for ISCO's stem cell-derived retinal tissue. ISCO is using its parthenogenetic stem cells to develop individual retinal pigmented epithelial ("RPE") cells and layered retinal structures internally and in collaboration with the laboratory of Dr. Hans Keirstead, Professor of Anatomy and Neurobiology at the University of California, Irvine. ISCO recently commenced a new research collaboration with UC Irvine to launch the next phase of its retinal studies with that institution, including preclinical trials. Potential therapeutic applications include retinitis pigmentosa, an untreatable inherited disease affecting about 100,000 Americans, and the dry form of age-related macular degeneration, a major cause of blindness in the elderly of the Western world. ISCO's goal is to establish functional proof of concept for RPE cellular therapy in models of human disease in the next twelve-eighteen months. Jointly referred to as Cytovis ("cyto" for cellular, "vis" for vision), these two cellular ophthalmology programs share a number of features and benefits. First, with the aging of the population worldwide and the growing number of work-related eye injuries in India, China and other major countries, the market opportunity is growing steadily. Second, there are strong pharmacoeconomic and quality-of-life rationales for full or partial vision restoration or delay of vision impairment diseases. Third, delivery of cells and tissues to the confined anatomy of the eye inherently provides for better safety and efficacy than, for example, the systemic circulation or the central nervous system. This will likely result in lower regulatory barriers and shorter and less costly development paths compared to that of anatomically deeper and more widespread diseases. Fourth, a number of eye diseases cannot be treated with surgery or traditional small molecule or protein therapeutics, yet cell and tissue therapy is proven to work but currently limited by availability of safe and sufficient cells and tissue from human donors. Finally, eye care development programs like CytoCor and CytoRet share a number of regulatory, development and commercial aspects that make it feasible for a relatively small team to produce substantial clinical outcomes and achieve competitive presence in the marketplace alone or in collaboration with dedicated partners. Brian Lundstrom, ISCO's President, says: "ISCO's proprietary parthenogenetic stem cell technology continues to form the foundation for the company's long term regenerative medicine therapy programs. In the nearer term, CytoCor and CytoRet's unique benefits in the field of cellular ophthalmology offer the potential for partnering and funding at a relatively early stage. Combined with the current and future revenue of Lifeline Cell Technology and the revenue potential of Lifeline Skin Care, scheduled for launch in the 4th quarter, Cytovis adds significantly to ISCO's diversity and value creation potential for its investor base in a cost-efficient fashion." ------------------------------------------------------------------------------------------------------ About SteroidStocks.com SteroidStocks.com is written and published by SteroidStocks.com employees. Readers are advised that this analysis report is issued solely for informational purposes. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a representation by the publisher nor a solicitation of the purchase or sale of any securities. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. SteroidStocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. For additional information, please visit www.steroidstocks.com or e-mail [email protected]. ((Comments on this story may be sent to [email protected])) (c) 2010 M2 COMMUNICATIONS |